Skip to main content
Clinical Trials/ISRCTN36901382
ISRCTN36901382
Completed
未知

Placebo-controlled assessment of the efficacy of a food supplement in improving face skin conditions and cellulite derived skin imperfections

ROELMI HPC0 sites66 target enrollmentMarch 16, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Fine lines/light wrinkles, dull skin and uneven skin tone and mild to moderate cellulite-derived skin imperfections
Sponsor
ROELMI HPC
Enrollment
66
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Registry
who.int
Start Date
March 16, 2023
End Date
April 10, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
ROELMI HPC

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy female subjects
  • 2\. Age between 35 and 65 (extremes included) years old
  • 3\. Phototype I to IV included, according to Fitzpatrick classification
  • 4\. Subjects showing fine lines/light wrinkles, dull skin and uneven skin tone
  • 5\. Subjects showing mild to moderate cellulite\-derived skin imperfections
  • 6\. 10 subjects per group showing visible dark circles
  • 7\. 10 subjects per group showing visible eyebags
  • 8\. Subjects who have not been involved in any other similar in the last 3 months
  • 9\. Subjects registered with Nation Health Service (NHS),
  • 10\. Subjects certifying the truthfulness of the personal data disclosed to the investigator

Exclusion Criteria

  • 1\. Subject does not meet the inclusion criteria
  • 2\. Subjects with acute or chronic diseases able to interfere with the outcome of the study or that are considered dangerous for the subject or incompatible with the study requirements
  • 3\. Subjects participating or planning to participate in other clinical trials
  • 4\. Subjects deprived of freedom by administrative or legal decision or under guardianship
  • 5\. Subjects not able to be contacted in case of emergency
  • 6\. Subjects admitted to a health or social facility
  • 7\. Subjects planning a hospitalization during the study
  • 8\. Subjects who participated in a similar study without respecting an adequate washout period
  • 9\. Subjects having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
  • 10\. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials